Induction of neutralizing antibodies against SARS-CoV-2 variants by a multivalent mRNA-lipid nanoparticle vaccine encoding SARS-CoV-2/SARS-CoV Spike protein receptor-binding domains in mice

TL;DR

This study shows that a multivalent mRNA vaccine can induce antibodies that neutralize multiple SARS-CoV and SARS-CoV-2 variants in mice.

Contribution

A novel multivalent mRNA-lipid nanoparticle vaccine design that induces cross-neutralizing antibodies against multiple coronaviruses and variants.

Findings

All vaccine constructs induced strong anti-RBD antibody responses in mice.

The heterodimeric vaccine elicited cross-neutralizing IgG against SARS-CoV, Wuhan-Hu-1, B.1.351, and B.1.617.2 variants.

Abstract

To address the need for multivalent vaccines against Coronaviridae that can be rapidly developed and manufactured, we compared antibody responses against SARS-CoV, SARS-CoV-2, and several variants of concern in mice immunized with mRNA-lipid nanoparticle vaccines encoding homodimers or heterodimers of SARS-CoV/SARS-CoV-2 receptor-binding domains. All vaccine constructs induced robust anti-RBD antibody responses, and the heterodimeric vaccine elicited an IgG response capable of cross-neutralizing SARS-CoV, SARS-CoV-2 Wuhan-Hu-1, B.1.351 (beta), and B.1.617.2 (delta) variants.

Figures